Smith Group Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Smith Group Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-70	Closed	-$7K	–	389
2021 Q2	$7K	Hold	70	–	–	﹤0.01%	333
2021 Q1	$8K	Sell	70 -1,890	-96%	-$257K	﹤0.01%	284
2020 Q4	$271K	Hold	1,960	–	–	0.02%	165
2020 Q3	$161K	Sell	1,960 -10	-0.5%	-$829	0.01%	178
2020 Q2	$154K	Sell	1,970 -30	-2%	-$1.99K	0.01%	173
2020 Q1	$89K	Hold	2,000	–	–	﹤0.01%	221
2019 Q4	$85K	Hold	2,000	–	–	﹤0.01%	247
2019 Q3	$86K	Buy	2,000 +320	+19%	+$17.4K	﹤0.01%	246
2019 Q2	$107K	Buy	1,680 +310	+23%	+$19.7K	﹤0.01%	233
2019 Q1	$95K	Sell	1,370 -4,600	-77%	-$263K	﹤0.01%	264
2018 Q4	$260K	Sell	5,970 -100	-2%	-$5.46K	0.01%	223
2018 Q3	$463K	Buy	6,070 +1,420	+31%	+$115K	0.01%	201
2018 Q2	$357K	Hold	4,650	–	–	0.01%	207
2018 Q1	$237K	Sell	4,650 -3,900	-46%	-$196K	0.01%	236
2017 Q4	$397K	Hold	8,550	–	–	0.01%	219
2017 Q3	$455K	Hold	8,550	–	–	0.02%	222
2017 Q2	$531K	Sell	8,550 -100	-1%	-$6.03K	0.02%	210
2017 Q1	$586K	Sell	8,650 -10	-0.1%	-$762	0.02%	179
2016 Q4	$609K	Sell	8,660 -100	-1%	-$7.09K	0.02%	179
2016 Q3	$621K	Hold	8,760	–	–	0.02%	172
2016 Q2	$428K	Sell	8,760 -710	-7%	-$45.9K	0.01%	190
2016 Q1	$600K	Buy	9,470 +1,840	+24%	+$120K	0.02%	166
2015 Q4	$856K	Buy	+7,630	New	+$763K	0.03%	180

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Smith Group Asset Management's RARE Position: Q3 2021 in Review

Smith Group Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2021, closing a stake of 70 shares — an estimated $7K sold.

Smith Group Asset Management first reported a position in RARE in Q4 2015 and held it in 23 quarters. The position peaked at $856K in Q4 2015. 222 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

Smith Group Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2021 after selling out during the quarter.
Smith Group Asset Management sold 70 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $7K.
Smith Group Asset Management first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 23 quarters.
Smith Group Asset Management's Ultragenyx Pharmaceutical position peaked at $856K in Q4 2015.
222 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.